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ABSTRACT: The contribution of Eli E. Sercarz to immunology and immunopathology has been remarkable and 
achieved many milestones in the understanding of the processes of the mechanisms fine-tuning immune responses. A 
part of his work was dedicated to the study of the deep complexity of the lymphocyte T cell repertoire and its importance 
during the physiologic development and disease, such as clonal heterogeneity of T cell responses. Starting from these 
studies, under his mentoring, we had the opportunity to implement the spectratyping method and apply it to human and 
experimental autoimmune diseases, obtaining intriguing results. The open question of this brief review is the possible 
role of this fine and complex technique, the immunoscope analysis, in the era of the big data and omics.
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I. INTRODUCTION
One of the main topics to which Eli Sercarz has 
given a profound contribution has been the study of 
the T cell repertoire, pioneering both methods and 
results achieved by the scientific community, some-
times many years later. Eli Sercarz was among the 
earliest researchers to apply spectratyping in human 
and experimental pathology. His work dissected the 
deep complexity of the lymphocyte T cell repertoire 
and its role during its physiologic development and 
in disease.1 His main focus was the implications of T 
cell receptor recognition in tolerance mechanisms,2,3 
providing new insights into autoimmune processes 
such as clonal heterogeneity of T cell responses,4,5 
epitope spreading6,7 and molecular mimicry.8 
Here we will highlight Eli Sercarz’s introduc-
tion of spectratyping, contributing to the deepening 
of molecular characterization of the T cell repertoire 
through immunoscope analysis9 and applying it, in 
more than a decade of studies, to human10 and ex-
perimental3,11,12 autoimmune disorders, infectious 
diseases,13 and cancer.14,15 His contribution in the 
field of basic immunology and immunopathology 
increased knowledge and allowed a better under-
standing of T cell response through the study of 
specificity.
II. TCR DIVERSITY
T cells play an important role in immune response 
through stimulation of the TCR, a surface receptor 
responsible for recognizing endogenous and exog-
enous antigens. Most TCRs combine one α with a 
β chain.16 The diversity of TCRs originates during 
early lymphoid differentiation from the random 
combination of variable (V) and joining (J) gene 
segments in the α-chain and V, diversity (D), and J 
gene segments in the β-chain germline gene. Spe-
cifically, random recombination of β chain gene 
segments generates the so-called complementarity 
determining region 3 (CDR3), which represents the 
loop with the most sequence diversity of the αβ TCR 
and accounts for the specificity and diversity of the 
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III. IMMUNOSCOPE
Immunoscope, also known as CDR3 BV-BJ spec-
tratyping, has been widely used to analyze CDR3 
length polymorphisms.18 This strategy is based on 
PCR technology that, through use of complementary 
constant (C), V, and J primers amplifies target cDNA 
corresponding to various rearranged transcripts with 
different CDR3 lengths from specific TCR V genes. 
Specifically, cDNA is subjected to PCR amplifica-
tion using a common C b primer in combination with 
V primers.19 V-C amplicons obtained from PCR are 
used as templates for subsequent run-off reactions, 
performed with a single-primer reaction for each J 
segment. After denaturation these products are re-
solved through capillary electrophoresis. Finally, 
analysis of spectratyping data is achieved by evalu-
ation of the area and shape of CDR3 profile peaks to 
establish the degree of skewing and oligoclonality.20 
IV. IMMUNOSCOPE IN OUR EXPERIENCE
Under the mentoring of Eli Sercarz, we first applied 
immunoscope in deep molecular characterization of 
the TCR repertoire in an experimental mouse model 
(SJL strain), detecting several myelin-specific (my-
elin-derived peptide, PLP139-151) public clonotypes 
and examining their contribution to pre-immune 
and post-immune CD4+ and CD8+ responses.12,18,21 
These observations were the first to hint that patho-
genic and nonpathogenic T cell repertoires specific 
to the same self-antigen could be different in their 
TCR use. Through the translation of these results to 
human pathology, we were later able to identify col-
lagen-specific T cells involved in the pathogenesis 
of rheumatoid arthritis, distinct from those present 
in healthy controls, that are detected during active 
phases.22 In addition, the presence of this pathogenic 
repertoire behaved as an early biomarker of respon-
siveness to treatment,23 leading to the potential use 
TCR-repertoire analysis in the personalization of 
therapy.24,25 Similar results have also been obtained 
in myasthenia gravis26 and multiple sclerosis (man-
uscript in preparation). These observations together 
may form the basis for future use of methods able 
to evaluate directly the T cell compartment in the 
clinical assessment of immune responsiveness in 
autoimmunity and cancer immunotherapy. In fact, 
we also applied the immunoscope method in a 
mouse model of cancer, where we were able to show 
that Treg cell depletion combined with anti-rErbb2 
vaccine blocks tumor progression by expanding la-
tent pools of low-avidity CD8+ T cells characterized 
by a specific antitumoral TCR repertoire, while the 
dominant, high-avidity CD8+ repertoire is depleted 
by central tolerance.19,27
In a rather unexpected turn, analysis of the TCR 
repertoire has led us to examine the ability of the 
infectious environment to modify directly T cell 
trafficking ability28 including the ability to infiltrate 
target organs and promote self-specific proinflam-
matory polarization as well as expansion of ag-spe-
cific FoxP3+ Tregs.29 
V.  IMMUNOSCOPE VERSUS  
NEXT-GENERATION SEQUENCING
Positive aspects of immunoscope include no re-
quirement for cloning before sequencing, ability 
to conduct multiple reactions in one lane, and per-
forming sequence reading using specific primers for 
each reaction. Finally, the single capillary instru-
ment allows automatization of all steps of sequenc-
ing.30 However, although this technique is still used 
in studying the TCR repertoire, it has important 
drawbacks. The main constraints are the lack of a 
full-repertoire perspective, the limited number of 
TCR sequences,17 and the potential loss of clonal 
aberrations or false-positive results, besides un-
avoidable bias due to the kinetics of hybridization 
during PCR amplification among primers and target 
TR genes. 
More sensitive approaches have recently been 
developed to investigate immune repertoires us-
ing next-generation sequencing (NGS), which has 
improved knowledge of TCR biology and reduced 
costs and time, achieving unbiased and quantita-
tive amplification of all TCR genes, including un-
known variants (Fig. 1). To totally nullify the PCR, 
we needed to wait for the third and fourth genera-
tions of sequencing; however, library construction 
protocols can introduce bias in sample composition, 
often elongating sequencing time.31,32 Nevertheless, 
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complex, so that thus far it cannot be easily trans-
ferred to peripheral blood in a clinical setting. 
For these reasons, it is still difficult to define 
one method as the gold standard, as all of them have 
advantages and disadvantages (Table 1). CDR3 
spectratyping is a good choice when interrogating 
a limited number of samples with known antigenic 
targets and when studying single-clone antigen-spe-
cific TCR. Despite its drawbacks, it remains a good 
technique to investigate the TCR repertoire,17 es-
pecially in immune-mediated disorders,33 consid-
ering its affordability and its simple experimental 
setting and data analysis. A valuable approach may 
be a first analysis of a limited number of samples 
by immunoscope, providing the definition of public 
TCRs that are of clinical interest (e.g., pathogenic 
or protective clones in autoimmune diseases, proin-
flammatory versus inhibitory T cell public clones in 
cancer immunotherapy), followed by focused NGS 
that may at this point be easily applied to clinical 
management. Of much interest, when examining 
patients using the two technologies, we found that 
the same sequences were highlighted by both (man-
uscript in preparation). Therefore, in the omics and 
big data era, immunoscope offers a comprehensive 
and immediate view of the diversity of the entire T 
cell compartment and should flank NGS rather than 
be completely replaced by it.
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